Please try another search
For the nine months ended 30 September 2018, Pernix Therapeutics Holdings Inc revenues decreased 17% to $86.4M. Net loss decreased 2% to $43.9M. Revenues reflect Net product sales decrease of 53% to $48.9M. Lower net loss reflects Depreciation and amortization expense decrease of 75% to $13.7M (expense), Change in fair value of contingent consi decrease of 58% to $143K (expense).
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 37.16 | 21.09 | 28.14 | 41.54 |
Gross Profit | 25.33 | 15.52 | 19.18 | 28.02 |
Operating Income | -10.39 | -4.44 | -9.07 | -24.74 |
Net Income | -11.85 | -13.51 | -18.58 | -32.42 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 274.77 | 166.63 | 178.4 | 204 |
Total Liabilities | 479.56 | 371.65 | 370.84 | 378.26 |
Total Equity | -204.79 | -205.02 | -192.44 | -174.26 |
Period Ending: | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -25.39 | -8.08 | -0.27 | -5.94 |
Cash From Investing Activities | -68.92 | 0.35 | -0 | 1.98 |
Cash From Financing Activities | 85.9 | -5.17 | -5.61 | 0.4 |
Net Change in Cash | -8.31 | -12.89 | -5.88 | -3.56 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review